After missing a key trial goal and getting a rare second chance from EU regulators, PTC Therapeutics’ ataluren is now the world’s first approved therapy for Duchenne muscular dystrophy, picking up a conditional European OK as the company awaits results from a late-stage study.

…read more

Source: PTC wins EU approval for its DMD drug as Phase III data pend


0 No comments